Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 19/20 | 0.65 |
| ▸ | ITGA4 | P13612 | 17/20 | 0.65 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.65 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.65 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.62 |
| ▸ | ITGAV | P06756 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181376 | 1.00 | ITGB1 (0.65) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL7538961 | 0.93 | ITGB1 (0.73) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL28742822 | 0.90 | ITGB1 (0.56) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL28742820 | 0.90 | ITGB1 (0.56) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL4066390 | 0.89 | L3MBTL1 (0.69) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL4072704 | 0.88 | ITGB1 (0.68) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL18068321 | 0.88 | ITGB1 (0.68) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL18047239 | 0.87 | ITGB1 (0.65) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL7428248 | 0.87 | ITGA4 (0.76) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL18047240 | 0.87 | ITGB1 (0.65) | ITGB1ITGA4ITGB7ITGA2ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | claimed |
| EP-1700850-B1 | Phenylalanine derivative | AJINOMOTO KK (JP) | 2015-07-15 | — | — | EP | disclosed |
| EP-2803667-A1 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2014-11-19 | — | — | EP | disclosed |
| EP-2615087-A2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-1916241-B1 | CRYSTAL OF PHENYLALANINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | AJINOMOTO KK (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8309561-B2 | N-(2,6-dichlorobenzoyl)-4-[1-methyl-7-(pyrrolidine-1-ylmethyl)-2,4-quinazoline-dione-3-yl]-L-phenylalanine trifluoroacetate; 4 integrin antagonist; antiinflammatory, anticarcinogenic agent, antiallergent; asthma, psoriasis, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation | AJINOMOTO CO., INC. (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8268844-B2 | Crystals of isopropyl ester of N-(2,6-dichlorobenzoyl)-4-[6-(methylamino)methyl-1-methyl-2,4-dioxo-1,4-dihydroquinazoline-3(2H)-yl]-l-phenylalanine hydrochloride, production method thereof and use thereof | AJINOMOTO CO., INC. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-2402326-A1 | Crystals of hydrochloride salts of a Phenylalanine Derivative, Production Method Thereof and Use Thereof as alpha4 integrin Inhibitors | Ajinomoto Co., Inc. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110009434-A1 | CRYSTALS OF ISOPROPYL ESTER OF N-(2,6-DICHLOROBENZOYL)-4-[6-(METHYLAMINO)METHYL -1-METHYL-2,4-DIOXO-1,4-DIHYDROQUINAZOLINE-3(2H)-YL]-L- PHENYLALANINE HYDROCHLORIDE, PRODUCTION METHOD THEREOF AND USE THEREOF | AJINOMOTO CO., INC. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7842700-B2 | Crystals of isopropyl ester of N-(2,6-dichlorobenzoyl)-4-[6-(methylamino)methyl-1-methyl-2,4-dioxo-1,4-dihydroquinazoline-3(2H)-yl]-L-phenylalanine hydrochloride, production method thereof and use thereof | AJINOMOTO CO., INC. (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20080108637-A1 | CRYSTALS OF PHENYLALANINE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | AJINOMOTO CO., INC. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108634-A1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-05-08 | — | — | US | disclosed |
| EP-1916241-A1 | CRYSTAL OF PHENYLALANINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Ajinomoto Co., Inc. (JP) | 2008-04-30 | — | — | EP | disclosed |
| US-7345049-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2008-03-18 | — | — | US | disclosed |
| EP-1700850-A1 | NOVEL PHENYLALANINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-20050222141-A1 | Novel phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108634-A1 | NOVEL PHENYLALANINE DERIVATIVES | ITGB4, ITGA4, ITGAV | ITGB1 10/4885ITGA4 2/4885ITGB7 13/4885 |
| US-20050222141-A1 | Novel phenylalanine derivatives | ITGB4, ITGA4, ITGAV | ITGB1 10/4885ITGA4 2/4885ITGB7 13/4885 |
| US-20110009434-A1 | CRYSTALS OF ISOPROPYL ESTER OF N-(2,6-DICHLOROBENZOYL)-4-[6-(METHYLAMINO)METHYL -1-METHYL-2,4-DIOXO-1,4-DIHYDROQUINAZOLINE-3(2H)-YL]-L- PHENYLALANINE HYDROCHLORIDE, PRODUCTION METHOD THEREOF AND USE THEREOF | ITGB4, ITGA4, ITGAL | ITGB1 8/4885ITGA4 2/4885ITGB7 14/4885 |
| US-20080108637-A1 | CRYSTALS OF PHENYLALANINE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | PAH, TYR, PEPD | ITGB1 4869/4885ITGA4 4848/4885ITGB7 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.